@article {2681,
	title = {Scaffold-based design and synthesis of potent N-type calcium channel blockers},
	journal = {Bioorganic \& Medicinal Chemistry Letters},
	volume = {19},
	number = {22},
	year = {2009},
	note = {ISI Document Delivery No.: 509PHTimes Cited: 5Cited Reference Count: 18Zamponi, Gerald W. Feng, Zhong-Ping Zhang, Lingyun Pajouhesh, Hossein Ding, Yanbing Belardetti, Francesco Pajouhesh, Hassan Dolphin, David Mitscher, Lester A. Snutch, Terrance P.},
	month = {Nov},
	pages = {6467-6472},
	type = {Article},
	abstract = {The therapeutic agents flunarizine and lomerizine exhibit inhibitory activities against a variety of ion channels and neurotransmitter receptors. We have optimized their scaffolds to obtain more selective N-type calcium channel blockers. During this optimization, we discovered NP118809 and NP078585, two potent N-type calcium channel blockers which have good selectivity over L-type calcium channels. Upon intraperitoneal administration both compounds exhibit analgesic activity in a rodent model of inflammatory pain. NP118809 further exhibits a number of favorable preclinical characteristics as they relate to overall pharmacokinetics and minimal off-target activity including the hERG potassium channel. (C) 2009 Elsevier Ltd. All rights reserved.},
	keywords = {BRAIN, CA2+ CHANNELS, Calcium channel blocker, Diphenylmethylpiperazine, N-type, OMEGA-CONOTOXIN, PAIN, SUBUNIT},
	isbn = {0960-894X},
	url = {<Go to ISI>://000271029600045},
	author = {Zamponi, G. W. and Feng, Z. P. and Zhang, L. Y. and Pajouhesh, H. and Ding, Y. B. and Belardetti, F. and Dolphin, D. and Mitscher, L. A. and Snutch, T. P.}
}
@article {1052,
	title = {Radiohalogens for imaging and therapy},
	journal = {Chemical Society Reviews},
	volume = {34},
	number = {2},
	year = {2005},
	note = {ISI Document Delivery No.: 890PETimes Cited: 34Cited Reference Count: 41},
	pages = {153-163},
	type = {Review},
	abstract = {Radiohalogens play a very important role in radiopharmaceuticals used for medical imaging ( now referred to as molecular imaging) and therapy applications. Development of new radiopharmaceuticals that have radiohalogens incorporated requires an understanding of parameters that are unique to chemistry involving these radionuclides. Those parameters include requirement for production and purification of the halogen radionuclides, as well as development of reaction conditions for use with high specific activity short-lived radionuclides. In this tutorial review, several radiohalogens, their radiolabeling chemistry and their application to medical imaging and therapy are discussed.},
	keywords = {BRAIN, CANCER, F-18, LIGAND, MONOCLONAL-ANTIBODIES, PET, POSITRON-EMISSION-TOMOGRAPHY, RADIOIODINATION, RADIOTHERAPY, SPECT},
	isbn = {0306-0012},
	url = {<Go to ISI>://000226522500005},
	author = {Adam,Michael J. and Wilbur, D. S.}
}
